Albuminuria, commonly measured as urine albumin-to-creatinine ratio (ACR), is an under-recognized component of chronic kidney disease (CKD) definition, staging and prognosis.
Albuminuria, elevated serum creatinine and low estimated glomerular filtration rate (eGFR) are key indicators of kidney decline. However, it is unclear if these biomarkers are independent predictors of kidney disease progression in people with type 2 diabetes mellitus (T2DM).
ACR and eGFR as predictors of cardio-renal outcomes in diabetes and kidney disease
Diabetic kidney disease, and chronic kidney disease attributed to diabetes, occurs in 20-40% of patients with diabetes. Acute kidney injury is also one of the most significant complications associated with COVID-19. Point-of-care testing for albumin-creatinine ratio is a valuable tool for monitoring at-risk patients, especially in combination with other comorbid parameters, such as HbA1c and lipids.
ACR point-of-care testing for diabetic kidney disease
The objective of these guidelines from the World Health Organization (WHO) is to provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings.
WHO guidelines on second-and third-line medicines and type of insulin for blood glucose control in diabetes
Following 19 months of consultation, this report sets out the Review on Antimicrobial Resistance’s final recommendations to tackle antimicrobial resistance (AMR) globally, as commissioned by sponsors, the UK Government and the Wellcome Trust.
Tackling drug-resistant infections globally: report and recommendations
The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease (CKD) represents an update to the 2012 KDIGO guideline.
KDIGO clinical practice guidelines for the management of blood pressure in chronic kidney disease
This updated guidance from the Infectious Diseases Society of America (IDSA) aims to provide an evidence-based diagnostic guideline to assist clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of COVID-19 molecular diagnostic testing.
IDSA guidelines on the diagnosis of COVID-19 molecular diagnostic testing
This updated guidance from the Infectious Diseases Society of America (IDSA) covers diagnosis,
treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza.
IDSA clinical practice guideline update on the management of seasonal influenza
en
Accedi ora
By using this site, you agree with our use of cookies.
